Participated · Series B · Aug 2026

Founded in 2020, BlissClub began as a women's activewear label and has expanded into a broader omnichannel athleisure business. The company has grown revenue by more than 60% year-on-year over the past two years and has expanded its retail footprint to more than 40 stores. Earlier this year the brand entered the menswear category, representing its category-expansion strategy. BlissClub is led by founder and CEO Minu Margeret and counts investors including Elevation Capital and Eight Roads Ventures. Following the Rs 160 crore funding round led by Singularity AMC, the company plans to use the capital to grow offline retail, strengthen product development and hire for its next stage. Existing investors and new participants, including Meesho cofounder Vidit Aatrey, also took part in the round.

Participated · Series B · Jun 2026

Exponent Energy develops a proprietary full-stack energy solution that enables 15-minute rapid charging for commercial EVs and offers a 3,000-cycle life warranty using regular lithium-ion cells. The company combines its battery and charger technology with the Exponent OTO mobility platform and Exponent ONE financing and asset-management arm to address energy, vehicles and access to capital. Exponent highlights interoperability across its charging stations, millions of charging sessions and more than three years of field performance as evidence of commercial readiness. It aims to become the preferred energy partner for OEMs and to power millions of commercial vehicles across India. The company plans to use new capital to expand into additional cities and vehicle categories and to strengthen R&D as it scales its energy and asset-management offerings.

Participated · Series B · Jun 2026

Immuneel Therapeutics develops CAR-T cell therapies, including Qartemi, aimed at treating blood cancers. The company describes CAR-T as a process that extracts a patient’s immune cells, modifies them to target cancer cells, and reinfuses them. Immuneel was founded in Bengaluru in 2019 and is led by Kiran Mazumdar-Shaw. Financially, the company recently raised Rs 100 crore ($10.5 million) in a Series B and previously secured $15 million in a 2022 Series A. Immuneel plans to use the new capital to ramp up production capacity for Qartemi and to expand its commercial or clinical efforts into Southeast Asia and the Middle East.

Participated · Series B · Jan 2026

Tenpoint Therapeutics, Ltd. is a global commercial biotech company focused on rejuvenating vision in the aging eye. Its lead product, YUVEZZI™ (carbachol and brimonidine tartrate ophthalmic solution 2.75% / 0.1%), is the first and only dual-agent eye drop approved for presbyopia, a condition that affects about 128 million people in the United States and roughly 2 billion worldwide. The company plans to launch YUVEZZI in early Q2, supported by a leadership team with extensive ophthalmology experience. Tenpoint emphasizes real-world needs by partnering closely with eye-care professionals to bring innovative treatments to market. Financially, the firm recently bolstered its balance sheet with $85 million in Series B equity financing and a $150 million non-dilutive term loan facility, bringing in both new and existing blue-chip investors. This capital positions Tenpoint to execute a large-scale commercial rollout while continuing to build its pipeline of therapies for the aging eye.

Participated · Equity · Jan 2026

AssetPlus provides a trust-led, advisor-centric wealth-management platform aimed at helping financial advisors deliver better investment outcomes for their clients. The company positions itself as an "assisted" wealth manager, combining technology with human advisory to serve India’s growing investor base. Its founding team, led by Vishranth Suresh and Awanish Raj, emphasizes disciplined execution, strong culture, and long-term integrity. AssetPlus has attracted marquee investors who share its vision of building a sustainable, advisor-first model. While the firm has not publicly disclosed operating metrics such as revenue or user numbers, the latest financing underscores investor confidence in its growth trajectory. The fresh capital is expected to support product enhancements, talent expansion, and deeper market penetration across India. Previous backing from Eight Roads and Rainmatter by Zerodha indicates a continued commitment from early supporters. Including the new funds, AssetPlus has secured ₹175 Crore to date, bolstering its financial position for the next phase of growth.